During the last decade, developments in the science of genetics and enormous advances in genetic technologies have altered our capability to understand diseases, make diagnoses and provide effective treatments. Transforming the world of prenatal testing, the advent of new DNA-based non-invasive prenatal testing (NIPT) has introduced a highly accurate screening strategy for fetal anueploidy.
The NIFTY® test (Non-Invasive Fetal TrisomY test) was the first NIPT to enter clinical testing in 2010 and has been validated by a study on nearly 147,000 pregnancies. As of 2017, nearly 2,800,000 NIFTY® tests have been carried out worldwide.
NIFTY® offers screening for some of the most common trisomies present at birth, inluding trisomy 21 (Down’s Syndrome), trisomy 18 (Edward’s Syndrome) and trisomy 13 (Patau Syndrome). NIFTY® also provides testing options for sex chromosomal aneuploidies, chromosomal deletions and gender.
pregnant women from week 10 of pregnancy
Under 10 working days
Peripheral blood sample
Low coverage whole genome sequencing
Sex Chromosome Aneuploidies
Down's Syndrome (T21)
Turner Syndrome (monosomy X)
Edwards Syndrome (T18)
Klinefelter Syndrome (XXY)
Patau Syndrome (T13)
Triple X Syndrome (XXX)
Jacob's Syndrome (XYY)
Prader-Willi/Angelman Syndrome (15q11.2)
Jacobsen Syndrome (11q23)
DiGeorge Syndrome II (10p14-p13)
Van der Woude Syndrome (1q32.2)
Ordering The NIFTY® Test is easy.
Physician orders test
Blood or saliva sample collected
Sample shipped to BGI and analyzed
Results sent to physician